MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
1930.58%
Quick Ratio
1930.58%
Cash Ratio
404.08%
Debt to Asset Ratio
8.58%
Unit: Thousand (K) dollars
Assets Breakdown
    • Short-term investments
    • Cash and cash equivalents
    • Long-term investments
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Derivative liability, non-curren...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
85,382
24,988
15,858
26,963
Short-term investments
314,894
57,005
82,478
84,654
Prepaid expenses and other current assets
7,607
6,685
6,913
2,139
Restricted cash, current portion
49
147
37
90
Total current assets
407,932
88,825
105,286
113,846
Long-term investments
71,878
-
-
-
Property and equipment, net
288
375
460
542
Goodwill
10,502
10,502
10,502
10,502
Restricted cash, net of current portion
183
183
210
210
Total assets
490,783
99,885
116,458
125,100
Accounts payable
3,347
356
137
474
Accrued expenses and other current liabilities
17,783
11,243
12,803
7,498
Derivative liability, current
-
-
0
0
Total current liabilities
21,130
11,599
12,940
7,972
Royalty obligation
2,000
2,000
2,000
2,000
Deferred tax liability, net
463
446
434
304
Derivative liability, non-current
18,530
17,520
18,000
23,160
Other long-term liabilities
0
0
35
117
Total liabilities
42,123
31,565
33,409
33,553
Temporary equity, values issued-Series DPreferred Stock
0
0
0
0
Temporary equity, values issued-Series EPreferred Stock
0
0
0
0
Common stock0.001 par value 200,000,000 shares authorized at june30, 2026 and december31, 2025 52,900,692 and 18,512,757 shares issued and outstanding at june30, 2026 and december31, 2025, respectively
53
25
18
18
Additional paid-in capital
953,700
536,453
531,485
526,290
Accumulated other comprehensive (loss) income
-583
-6
68
41
Accumulated deficit
-504,510
-468,152
-448,522
-434,802
Total stockholders equity
448,660
68,320
83,049
91,547
Total liabilities, mezzanine equity and stockholders equity
490,783
99,885
116,458
125,100
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term investments$314,894K (343.69%↑ Y/Y)Cash and cashequivalents$85,382K (101.90%↑ Y/Y)Prepaid expenses andother current assets$7,607K (299.74%↑ Y/Y)Restricted cash, currentportion$49K (145.00%↑ Y/Y)Total current assets$407,932K (254.15%↑ Y/Y)Long-term investments$71,878K Goodwill$10,502K (0.00%↑ Y/Y)Property and equipment,net$288K (-58.02%↓ Y/Y)Restricted cash, net ofcurrent portion$183K (-12.86%↓ Y/Y)Total assets$490,783K (287.72%↑ Y/Y)Total liabilities,mezzanine equity and...$490,783K (287.72%↑ Y/Y)Total stockholdersequity$448,660K (329.04%↑ Y/Y)Total liabilities$42,123K (91.39%↑ Y/Y)Accumulated deficit-$504,510K (-24.82%↓ Y/Y)Accumulated othercomprehensive (loss) income-$583K (-1614.71%↓ Y/Y)Additional paid-in capital$953,700K (87.45%↑ Y/Y)Total currentliabilities$21,130K (128.21%↑ Y/Y)Derivative liability,non-current$18,530K (80.60%↑ Y/Y)Royalty obligation$2,000K (0.00%↑ Y/Y)Deferred tax liability,net$463K (58.02%↑ Y/Y)Common stock0.001 parvalue 200,000,000...$53K (381.82%↑ Y/Y)Accrued expenses andother current...$17,783K (172.62%↑ Y/Y)Accounts payable$3,347K (41.46%↑ Y/Y)

Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics, Inc. (AVTX)